Page 170 - Read Online

Page 20 of 21 Yang et al. Hepatoma Res 2023;9:48 https://dx.doi.org/10.20517/2394-5079.2023.68

61. Iversen L, Tu HL, Lin WC, et al. Molecular kinetics. Ras activation by SOS: allosteric regulation by altered fluctuation dynamics.
Science 2014;345:50-4. DOI
62. Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther
2021;6:386. DOI PubMed PMC
63. Zhu C, Guan X, Zhang X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer
2022;21:159. DOI PubMed PMC
64. Parikh K, Banna G, Liu SV, et al. Drugging KRAS: current perspectives and state-of-art review. J Hematol Oncol 2022;15:152. DOI
PubMed PMC
65. Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a
phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21:1234-43. DOI
66. Salama AKS, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with BRAF V600E mutations: results of the
NCI-MATCH trial subprotocol H. J Clin Oncol 2020;38:3895-904. DOI PubMed PMC
V600
67. Subbiah V, Puzanov I, Blay JY, et al. Pan-cancer efficacy of vemurafenib in BRAF -mutant non-melanoma cancers. Cancer
Discov 2020;10:657-63. DOI PubMed PMC
68. Kim JW, Lee KH, Kim JW, et al. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer
patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. Br J Cancer 2019;121:332-9. DOI PubMed PMC
69. Subbiah V, Cassier PA, Siena S, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the
phase 1/2 ARROW trial. Nat Med 2022;28:1640-5. DOI PubMed PMC
70. Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid
tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022;23:1261-73.
DOI PubMed
71. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018;15:731-47. DOI
PubMed PMC
72. Yoshino T, Pentheroudakis G, Mishima S, et al. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations
for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol
2020;31:861-72. DOI PubMed
73. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5:25-34.
DOI PubMed PMC
74. Scott LJ. Larotrectinib: first global approval. Drugs 2019;79:201-6. DOI PubMed
75. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three
phase 1/2 clinical trials. Lancet Oncol 2020;21:531-40. DOI PubMed PMC
76. Demetri GD, De Braud F, Drilon A, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK
fusion-positive solid tumors. Clin Cancer Res 2022;28:1302-12. DOI PubMed PMC
77. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-
high solid tumors. Clin Cancer Res 2019;25:3753-8. DOI PubMed
78. Richman S. Deficient mismatch repair: read all about it (review). Int J Oncol 2015;47:1189-202. DOI PubMed PMC
79. Jung J, Heo YJ, Park S. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid
tumor: a real-world pan-tumor analysis. J Immunother Cancer 2023;11:e006454. DOI PubMed PMC
80. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science
2017;357:409-13. DOI
81. Borghaei H, Ciuleanu TE, Lee JS, et al. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-
small-cell lung cancer: a pooled analysis. Ann Oncol 2023;34:173-85. DOI
82. Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers:
updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33:929-38. DOI PubMed
83. Andre T, Berton D, Curigliano G, et al. Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-
deficient (dMMR) solid cancers: results from GARNET study. JCO 2021;39:9. DOI
84. Schenker M, Burotto M, Richardet M, et al. Abstract CT022: checkMate 848: a randomized, open-label, phase 2 study of nivolumab
in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor
mutational burden. Cancer Res 2022;82:CT022. DOI
85. Kim RD, Chung V, Alese OB, et al. A Phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary
tract cancer. JAMA Oncol 2020;6:888-94. DOI PubMed PMC
86. Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid
2022;1:EVIDoa2200015. DOI
87. Kelley RK, Ueno M, Yoo C, et al; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin
compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1853-65. DOI PubMed
88. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic
cancers: a report from the ESMO precision medicine working group. Ann Oncol 2020;31:1491-505. DOI
89. Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice